Bacterial Vaginosis
Conditions
Keywords
Recurrence of Bacterial Vaginosis
Brief summary
The POLARIS trial is designed as a multicenter, open label, non-comparative, 3 months, clinical study. Interventional, non-controlled, multicenter trial with a prospective design on one cohort of patients
Detailed description
To evaluate the efficacy of Polybactum® administered for 3 cycles (one cycle/month) in reducing the rate of recurrence of BV in women cured with vaginal metronidazole and to compare the results of the treatment with the rate of recurrence reported in appropriate selected international literature. Therefore, the Polybactum® early administration should be able to modify the basal individual risk of BV recurrence.
Interventions
DEVICEPolybactum®
3 cycles treatment one per month.. Duration of one cycle: 1 week; administration for each cycle: 1 ovule at Day 1, 1 ovule at Day 4; 1 ovule at Day 7.In the two following cycles, the same treatment will be repeated immediately after the end of the first and second menstrual bleeding.
Sponsors
Opera CRO, a TIGERMED Group Company
Effik Italia S.p.A.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women above 18 years. * BV diagnosed by Amsel criteria (see Annex 3) in the 6-9 days before study, and cured with metronidazole vaginal formulation (gel for 5 days or ovules for 7 days). * Diagnosis of RBV (at least 2 episodes of BV in the last 12 months including the BV cured before baseline). * Non lactating women or lactating non amenorrheic women. * Read and signed informed consent.
Exclusion criteria
* Pregnancy. * Candidiasis or mixed vaginitis. * HIV or other immunodeficiency. * Known allergy to metronidazole or to Polybactum® ingredients. * Sex workers. * Menstruation or pre-menopause/menopause. * Patients concomitantly included in different interventional clinical trials. * Unwillingness to provide the informed consent to the trial. * Time between the last day of last menses and baseline visit \> 16 days or ≤5 days.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Amsel criteria laboratory diagnostic | 3 months | Signs and symptoms of Bacterial Vaginosis assesed also by patients diary (vaginal discharge, burning, erythema, dyspareunia) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Lactobacilli counting | 3 months | The rate of return to normality of vaginal microflora through Lactobacilli counting |
Other
| Measure | Time frame | Description |
|---|---|---|
| Patient's diary | 3 months | Global Assessment of Efficacy by Patient's diary |
Countries
Romania
Outcome results
None listed